Antares Pharma (NASDAQ:ATRS) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Antares Pharma (NASDAQ:ATRSGet Rating) from a hold rating to a buy rating in a research note released on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $6.25 price objective on the specialty pharmaceutical company’s stock.

According to Zacks, “Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes its needle-free injector systems for the delivery of insulin and growth hormone in over 20 countries and an estradiol transdermal patch for hormone replacement therapy. “

Several other research analysts also recently weighed in on ATRS. HC Wainwright downgraded Antares Pharma from a buy rating to a neutral rating and set a $5.60 target price on the stock. in a research note on Thursday, April 14th. Truist Financial downgraded Antares Pharma from a buy rating to a hold rating and dropped their target price for the stock from $7.00 to $5.60 in a research note on Wednesday, April 13th. Raymond James downgraded Antares Pharma from a strong-buy rating to a market perform rating in a research note on Thursday, April 14th. StockNews.com downgraded Antares Pharma from a buy rating to a hold rating in a research note on Wednesday, April 20th. Finally, LADENBURG THALM/SH SH downgraded Antares Pharma from a buy rating to a neutral rating in a research note on Thursday, April 14th. Six investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of Hold and an average price target of $5.76.

Shares of NASDAQ:ATRS opened at $5.59 on Wednesday. Antares Pharma has a 12-month low of $3.11 and a 12-month high of $5.59. The business’s fifty day simple moving average is $4.42 and its 200-day simple moving average is $3.81. The company has a market capitalization of $954.66 million, a PE ratio of 20.70 and a beta of 1.15. The company has a current ratio of 2.96, a quick ratio of 2.76 and a debt-to-equity ratio of 0.10.

Antares Pharma (NASDAQ:ATRSGet Rating) last announced its quarterly earnings results on Thursday, March 3rd. The specialty pharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.01. Antares Pharma had a return on equity of 12.33% and a net margin of 25.16%. The business had revenue of $48.73 million for the quarter, compared to the consensus estimate of $46.25 million. During the same period last year, the business posted $0.03 EPS. Research analysts predict that Antares Pharma will post 0.08 EPS for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of ATRS. Stonepine Capital Management LLC lifted its position in Antares Pharma by 769.9% during the 4th quarter. Stonepine Capital Management LLC now owns 2,297,360 shares of the specialty pharmaceutical company’s stock worth $8,202,000 after acquiring an additional 2,033,260 shares during the period. Russell Investments Group Ltd. lifted its position in Antares Pharma by 166.6% during the 1st quarter. Russell Investments Group Ltd. now owns 3,045,999 shares of the specialty pharmaceutical company’s stock worth $12,487,000 after acquiring an additional 1,903,508 shares during the period. Rubric Capital Management LP lifted its holdings in shares of Antares Pharma by 8.0% in the 4th quarter. Rubric Capital Management LP now owns 10,800,000 shares of the specialty pharmaceutical company’s stock valued at $38,556,000 after buying an additional 800,000 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of Antares Pharma by 311.3% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,037,736 shares of the specialty pharmaceutical company’s stock valued at $4,255,000 after buying an additional 785,443 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Antares Pharma by 167.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,139,703 shares of the specialty pharmaceutical company’s stock valued at $4,069,000 after buying an additional 713,905 shares during the period. 50.41% of the stock is owned by institutional investors.

Antares Pharma Company Profile (Get Rating)

Antares Pharma, Inc, a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems.

Read More

Get a free copy of the Zacks research report on Antares Pharma (ATRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.